Lilly, BI approach CV-benefit label change for SGLT2 med Jardiance

Carly Helfand

Eli and Boehringer Ingelheim are one step closer to an important for contender .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS